Gail L Brown

Summary

Publications

  1. pmc Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Columbia University Medical Center, New York, NY, USA
    J Hematol Oncol 5:18. 2012
  2. pmc Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
    Naomi Galili
    Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA
    J Hematol Oncol 5:20. 2012
  3. pmc Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor
    Roger M Lyons
    Cancer Care Centers of South Texas, US Oncology, San Antonio, TX 78229, USA
    J Hematol Oncol 4:43. 2011
  4. pmc Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
    Azra Raza
    University of Massachusetts Medical Center, Worcester, MA, USA
    J Hematol Oncol 2:20. 2009
  5. pmc Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
    John J Kavanagh
    Telik, Inc, Palo Alto, CA, USA
    J Hematol Oncol 3:9. 2010

Collaborators

  • John J Kavanagh
  • Azra Raza
  • Naomi Galili
  • Roger M Lyons
  • Olga B Botvinnik
  • Ruben A Mesa
  • Guillermo Garcia-Manero
  • Deborah Mulford
  • Margarita R Brooks
  • Pablo Tamayo
  • David P Steensma
  • Jill P Mesirov
  • Scott E Smith
  • Mikkael A Sekeres
  • Ralph Boccia
  • Shelby Young
  • Sharon T Wilks
  • Stephanie Williams
  • Leonel Ochoa
  • Lisa Meng
  • Zeev Estrov
  • Lawrence Piro
  • Natalie Callander
  • Peter Emanuel
  • Stefan Faderl
  • Peter Curtin
  • Marsha Jones
  • James G Keck
  • Howard Burris
  • Richard A Larson

Detail Information

Publications5

  1. pmc Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Columbia University Medical Center, New York, NY, USA
    J Hematol Oncol 5:18. 2012
    ..Ezatiostat, a glutathione S-transferase P1-1 inhibitor, promotes the maturation of hematopoietic progenitors and induces apoptosis in cancer cells...
  2. pmc Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
    Naomi Galili
    Department of Medicine, Division of Hematology and Oncology, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA
    J Hematol Oncol 5:20. 2012
    ..The success of that study was based in part on the fact that the profile for response was linked to the biology of the disease...
  3. pmc Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor
    Roger M Lyons
    Cancer Care Centers of South Texas, US Oncology, San Antonio, TX 78229, USA
    J Hematol Oncol 4:43. 2011
    ..These results suggest potential roles for ezatiostat in the treatment of patients with ICN who are not responsive to G-CSF, as an oral therapy alternative, or as an adjunct to G-CSF, and further studies are warranted...
  4. pmc Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
    Azra Raza
    University of Massachusetts Medical Center, Worcester, MA, USA
    J Hematol Oncol 2:20. 2009
    ..In phase 2, ezatiostat was administered on 2 dose schedules: 600 mg/m2 IV on days 1 to 5 or days 1 to 3 of a 21-day treatment cycle...
  5. pmc Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
    John J Kavanagh
    Telik, Inc, Palo Alto, CA, USA
    J Hematol Oncol 3:9. 2010
    ..The primary endpoints were objective response rate (ORR) and progression-free survival (PFS)...